Renalytix to present at American Society of Nephrology Kidney Week

Kidneys Closeup

Renalytix on Monday announced that four scientific presentations have been accepted at the upcoming American Society of Nephrology (ASN) Kidney Week in Orlando, FL, November 3-6, 2022.

London-based Renalytix specializes in kidney-health bioprognosis. The firm’s KidneyIntelX test, which uses blood-based biomarkers and clinical variables to identify and predict kidney function decline, received breakthrough device status from the U.S. Food and Drug Administration in May.

The presentations will include a cost-effectiveness analysis supporting population-based KidneyIntelX testing for the prognosis of early-stage diabetic kidney disease (DKD) for Medicare patients, as well as findings from a multiyear study at a major healthcare system highlighting disparities in healthcare access.

Kidney disease is a global public health epidemic, with over 850 million people affected worldwide. Nearly 95% of those affected are in CKD’s early stages. According to the Centers for Disease Control and Prevention (CDC), about 15% of adults (over 37 million people) in the U.S. have chronic kidney disease (CKD).

Despite its prevalence, CKD is underdiagnosed and undertreated, with up to 90% of those with CKD unaware they have the condition, Renalytix noted, adding that while early-stage CKD may be asymptomatic, which contributes to this rate of underdiagnosis, 40% of adults with severe CKD are also unaware they have the condition.

Spinal fluid tests may aid PET scans of Alzheimer's disease
2022 03 02 20 27 6315 2022 03 04 Tau Biomarkers 400
Page 1 of 3
Next Page